The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Study findings support The End-Stage Renal Disease Quality Incentive Program’s composite measure of facility performance, which is revised annually.
Black patients without high-risk APOL1 alleles did not have higher risks for kidney failure.
Furthermore, use of anticoagulants induces higher incidence of GI bleeding in hemodialysis versus peritoneal dialysis patients
GDF-15 adds predictive value to the HAS-BLED score for assessing major bleeding risk.
The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.
Under Medicare, patients with kidney failure often must choose between continuing dialysis or enrolling in hospice.
Few facilities report having environmental sustainability strategy in place or undertaking sustainability audits
In the hemodialysis population, cardiovascular calcifications result from excess phosphate and calcium, as well as reduced activity of inhibitors of calcification, such as matrix Gla protein.
Optimizing hemodialysis timing before surgery might improve postoperative outcomes.